Health
Soufflé gets $135M for three RNA medicines
A Bob Langer-affiliated startup has collected a megaround financing to advance at least three experimental oligonucleotide medicines. The Massachusetts and Germany biotech, Soufflé Therapeutics, uncorked a fresh $135 million in…
- Published
- (2026-10-13)
- Outlet
- Endpoints News
- Section
- Health
- Length here
- Headline and 30-word snippet. The full article is at the source.
More from Endpoints News and around the same time
Employers accuse UnitedHealth of overpaying medical claimsSix large US companies sued UnitedHealth Group, accusing the health insurance giant of overpaying for workers’ medical claims and driving up their costs. Aramark, Whirlpool, Grainger, Kraft Heinz Foods, Ralph Lauren and Sterling…Microsoft's AI gives more accurate diagnoses than doctors, study findsMicrosoft says its AI system was around twice as accurate as doctors in diagnosing cases from a medical journal and from emergency room visits, as the tech giant looks to bring AI into clinical care. ...WuXi AppTec raises revenue forecast again in the face of DoD court caseWuXi AppTec's dispute with the US Department of Defense over its designation as a Chinese military company isn't standing in the way of its performance: The manufacturer raised its 2026 guidance again and is accelerating ...Roche’s changing plans show how MFN is complicating European drug launchesRoche will seek European approval for its promising new breast cancer pill giredestrant later than it once expected, highlighting how US drug pricing pressure may be affecting pharmaceutical companies’ launch strategies…Beyond cancer vaccine, how did Merck’s oncology pipeline do at #ESMO26?MADRID — Much of the coverage on Merck at the European Society for Medical Oncology congress centered on its Moderna-partnered cancer vaccine trial. But the company is actually at the meeting with more than two ...Aspen, Bambusa target $135M IPOs; AstraZeneca vs. Takeda in gastric cancer ADCsPlus news about Hutchmed, Johnson &; Johnson, Jazz Pharmaceuticals, Novartis, Roche and Oruka Therapeutics. Aspen, Bambusa both eye $135M IPOs: Aspen Neuroscience plans to sell 9.38 million shares {$ASPE} between $15 ...This page holds the headline and a short snippet as published by Endpoints News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
